skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 3,468  for All Library Resources

Results 1 2 3 4 5 next page
Refined by: resource type: Newsletter Articles remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Achieve Life Sciences (ACHV: $5.03) accelerates rise, up 9.1% in 2 days; +42c [9.1%] Vol Index 1.8 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Achieve Life Sciences (ACHV: $5.03) accelerates rise, up 9.1% in 2 days; +42c [9.1%] Vol Index 1.8 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 15, 2024

Digital Resources/Online E-Resources

2
European Society of Cardiology: Weight Loss Drug Linked With Reduced Need for Diuretics in Heart Failure Patients
Material Type:
Newsletter Article
Add to My Research

European Society of Cardiology: Weight Loss Drug Linked With Reduced Need for Diuretics in Heart Failure Patients

Targeted News Service, 2024

Targeted News Service

Digital Resources/Online E-Resources

3
Achieve Life Sciences (ACHV: $4.81) up 6.2% in 2 days, hits 101-day high; +28c [6.2%] Vol Index 1.6 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Achieve Life Sciences (ACHV: $4.81) up 6.2% in 2 days, hits 101-day high; +28c [6.2%] Vol Index 1.6 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 14, 2024

Digital Resources/Online E-Resources

4
Achieve Life Sciences (ACHV: $4.61) lifts 1.8% on rising relative strength; reports Loss of $6.5m; +8c [1.8%] Vol Index 1.5 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Achieve Life Sciences (ACHV: $4.61) lifts 1.8% on rising relative strength; reports Loss of $6.5m; +8c [1.8%] Vol Index 1.5 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 11, 2024

Digital Resources/Online E-Resources

5
New Pulmonary Syndrome Linked to Covid-19 Discovered
Material Type:
Newsletter Article
Add to My Research

New Pulmonary Syndrome Linked to Covid-19 Discovered

CE Noticias Financieras, 2024

CE Noticias Financieras English, Latin America - Distributed by ContentEngine LLC

Digital Resources/Online E-Resources

6
Achieve Life Sciences (ACHV: $4.53) down 4.2% in 2 days; -20c [4.2%]
Material Type:
Newsletter Article
Add to My Research

Achieve Life Sciences (ACHV: $4.53) down 4.2% in 2 days; -20c [4.2%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 10, 2024

Digital Resources/Online E-Resources

7
Achieve Life Sciences (ACHV: $4.70) decreases; -3c [0.6%]
Material Type:
Newsletter Article
Add to My Research

Achieve Life Sciences (ACHV: $4.70) decreases; -3c [0.6%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 9, 2024

Digital Resources/Online E-Resources

8
Achieve Life Sciences (ACHV: $4.73) continues significant uptrend, gains 3.5%; +16c [3.5%]
Material Type:
Newsletter Article
Add to My Research

Achieve Life Sciences (ACHV: $4.73) continues significant uptrend, gains 3.5%; +16c [3.5%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 8, 2024

Digital Resources/Online E-Resources

9
National Yang Ming Chiao Tung Univ Seeks Patent for Neurovascular Age Prediction System Based on White Matter and Method Thereof
Material Type:
Newsletter Article
Add to My Research

National Yang Ming Chiao Tung Univ Seeks Patent for Neurovascular Age Prediction System Based on White Matter and Method Thereof

Global IP News. Medical Patent News, 2024

Copyright© 2024, Globalipnews.com

Digital Resources/Online E-Resources

10
Achieve Life Sciences Announces Publication Of Cytisinicline Vaping Cessation Trial Results In JAMA Internal Medicine; Phase 2 ORCA-V1 Trial Showed Treatment With Cytisinicline More Than Doubled Odds Of Quitting E-Cigarettes Compared With Placebo
Material Type:
Newsletter Article
Add to My Research

Achieve Life Sciences Announces Publication Of Cytisinicline Vaping Cessation Trial Results In JAMA Internal Medicine; Phase 2 ORCA-V1 Trial Showed Treatment With Cytisinicline More Than Doubled Odds Of Quitting E-Cigarettes Compared With Placebo

Benzinga Newswires, 2024

2020 Benzinga.com - Benzinga does not provide investment advice. All rights reserved.

Digital Resources/Online E-Resources

11
Press Release: Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
Material Type:
Newsletter Article
Add to My Research

Press Release: Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

Dow Jones Institutional News, 2024

Copyright Dow Jones & Company Inc. May 6, 2024

Digital Resources/Online E-Resources

12
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
Material Type:
Newsletter Article
Add to My Research

Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

NASDAQ OMX's News Release Distribution Channel, 2024

GlobeNewswire, Inc.

Digital Resources/Online E-Resources

13
Society for Cardiovascular Angiography Interventions: TAVR Is Associated With Lower In-Hospital Complications in Patients With Aortic Stenosis and Cardiogenic Shock Compared to SAVR
Material Type:
Newsletter Article
Add to My Research

Society for Cardiovascular Angiography Interventions: TAVR Is Associated With Lower In-Hospital Complications in Patients With Aortic Stenosis and Cardiogenic Shock Compared to SAVR

Targeted News Service, 2024

Targeted News Service

Digital Resources/Online E-Resources

14
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
Material Type:
Newsletter Article
Add to My Research

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

NASDAQ OMX's News Release Distribution Channel, 2024

GlobeNewswire, Inc.

Digital Resources/Online E-Resources

15
Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On Therapies
Material Type:
Newsletter Article
Add to My Research

Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On Therapies

PR Newswire, 2024

Copyright PR Newswire Association LLC Apr 12, 2024

Digital Resources/Online E-Resources

16
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Material Type:
Newsletter Article
Add to My Research

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

NASDAQ OMX's News Release Distribution Channel, 2024

GlobeNewswire, Inc.

Digital Resources/Online E-Resources

17
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
Material Type:
Newsletter Article
Add to My Research

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Business Wire, 2024

Copyright Business Wire 2024

Digital Resources/Online E-Resources

18
Eight-bagger Applied Therapeutics (APLT: $6.38) increases; +5c [0.8%]
Material Type:
Newsletter Article
Add to My Research

Eight-bagger Applied Therapeutics (APLT: $6.38) increases; +5c [0.8%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd Apr 3, 2024

Digital Resources/Online E-Resources

19
American Academy of Sleep Medicine: Health Care Utilization is Increased in High-Risk Children Who Have a Sleep Disorder
Material Type:
Newsletter Article
Add to My Research

American Academy of Sleep Medicine: Health Care Utilization is Increased in High-Risk Children Who Have a Sleep Disorder

Targeted News Service, 2024

Targeted News Service

Digital Resources/Online E-Resources

20
Applied Therapeutics (APLT: $6.30) plunges 7.4% on slipping relative strength; -50c [7.4%] Vol Index 1.2 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Applied Therapeutics (APLT: $6.30) plunges 7.4% on slipping relative strength; -50c [7.4%] Vol Index 1.2 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd Apr 2, 2024

Digital Resources/Online E-Resources

Results 1 - 20 of 3,468  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 2001  (22)
  2. 2001 To 2006  (124)
  3. 2007 To 2012  (421)
  4. 2013 To 2019  (854)
  5. After 2019  (2,048)
  6. More options open sub menu

Language 

  1. English  (3,433)
  2. German  (16)
  3. Spanish  (8)
  4. Portuguese  (5)
  5. Italian  (3)
  6. French  (3)
  7. More options open sub menu

Searching Remote Databases, Please Wait